This material is for healthcare professionals practicing in Middle East only.
Reporting suspected adverse reactions of medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals and patients are asked to report any suspected adverse reactions via:
Kuwait/UAE: the national reporting schemes as applicable.
Saudi Arabia: the National Pharmacovigilance Centre (NPC) unified number: 19999 or email: email@example.com
Adverse reactions may also be reported directly to Gilead.
Adverse reactions related to Gilead products may be reported directly to Gilead via:
UAE/Saudi Arabia: Safety_FC@gilead.com